Trastuzumab Duocarmazine in Pretreated Her2-Positive Breast Cancer: Has the “TULIP” Bloomed a Bit Too Late?

Trastuzumab Duocarmazine in Pretreated Her2-Positive Breast Cancer: Has the “TULIP” Bloomed a Bit Too Late?

Saved in:

Bibliographic Details
Main Author:	Akhil Santhosh
Format:	Article
Language:	English
Published:	Thieme Medical and Scientific Publishers Pvt. Ltd. 2025-08-01
Series:	Indian Journal of Medical and Paediatric Oncology
Online Access:	http://www.thieme-connect.de/DOI/DOI?10.1055/s-0045-1808100
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Disitamab vedotin in preclinical models of HER2-positive breast and gastric cancers resistant to trastuzumab emtansine and trastuzumab deruxtecan
by: Negar Pourjamal, et al.
Published: (2025-03-01)

Trastuzumab deruxtecan: A quantum leap in HER2-positive breast cancer
by: Manikandan Dhanushkodi
Published: (2019-01-01)

Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent?
by: Yu Ishimine, et al.
Published: (2015-01-01)

Trastuzumab Deruxtecan for HER2-Positive Breast Cancer with Central Nervous System Metastasis
by: Hiroaki Yamane, et al.
Published: (2024-12-01)

CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
by: Fei Xing, et al.
Published: (2023-01-01)

DB-1310, a HER3-targeting antibody-drug conjugate, has synergistic anti-tumor activity with trastuzumab in HER2- and HER3-expressing breast cancer
by: Xi Li, et al.
Published: (2025-03-01)

PAK5 promotes the trastuzumab resistance by increasing HER2 nuclear accumulation in HER2-positive breast cancer
by: Xin Zhao, et al.
Published: (2025-04-01)

How the tulip breaking virus creates striped tulips
by: Aidan A. Wong, et al.
Published: (2025-01-01)

Too Soon / Too Late
by: Daniel Ross
Published: (2023-12-01)

Effect of HER2 Ile655Val polymorphism on the response to trastuzumab treatment in HER2-positive breast cancer patients
by: Zohreh Gheibipour, et al.
Published: (2025-07-01)

Trastuzumab deruxtecan for the late lines of treatment for HER2-low metastatic breast cancer: a clinical case
by: R. A. Murashko, et al.
Published: (2025-03-01)

Subcutaneous Trastuzumab: An Observational Study of Safety and Tolerability in Patients With Early HER2-Positive Breast Cancer
by: Iris Otoya, et al.
Published: (2024-01-01)

Notch and Hedgehog Signalling Axis Drive Senescence in HER2-Positive Breast Cancer Resistant to Trastuzumab
by: Asiye Büşra Boz Er, et al.
Published: (2024-12-01)

Trastuzumab Rechallenge in HER2-Positive Metastatic Breast Cancer: A Promising Strategy for Enhanced Progression-Free Survival Post Ado-Trastuzumab Emtansine Progression
by: Yunus Emre Altıntaş, et al.
Published: (2024-12-01)

Prognostic Significance of Delays in Initiation of Adjuvant Trastuzumab-Based Therapy in Patients with HER2-Positive Breast Cancer
by: Gavin P. Dowling, et al.
Published: (2025-05-01)

Involvement of microRNAs-449/FASN axis in response to trastuzumab therapy in HER2-positive breast cancer
by: Ana Lameirinhas, et al.
Published: (2025-03-01)

Investigation of <i>ITGB3</i> Heterogeneity to Overcome Trastuzumab Resistance in HER2-Positive Breast Cancer
by: Asiye Busra Boz Er
Published: (2024-12-01)

Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer
by: Gabriel L. Fiszman, et al.
Published: (2011-01-01)

Mixed adenoneuroendocrine carcinoma with loss of HER2 positivity after trastuzumab-based chemotherapy for HER2-positive gastric cancer: a case report
by: Hiromi Nagata, et al.
Published: (2020-01-01)

Correction of scientific literature: Too little, too late!
by: Lonni Besançon, et al.
Published: (2022-03-01)

Trastuzumab emtansine in locally advanced or metastatic HER2 positive breast cancer; GENESIS-SEFH drug evaluation report
by: Patricia Miranda Romero, et al.
Published: (2015-02-01)

Complete response to trastuzumab-deruxtecan (Enhertu, T-DXd) in HER2-positive stage IVB uterine carcinosarcoma
by: Michael Kim, et al.
Published: (2025-08-01)

A Case of Ventricular Arrhythmia in a Patient With HER2-Positive Gastric Cancer Receiving Trastuzumab
by: Naoto Takahashi, et al.
Published: (2025-01-01)

HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumab
by: Rodrigo Sánchez-Bayona, et al.
Published: (2025-04-01)

The European Pillar of Social Rights: Too Little, Too Late?
by: Florin Bonciu
Published: (2018-06-01)

Targeting SLC7A11-mediated cysteine metabolism for the treatment of trastuzumab-resistant HER2-positive breast cancer
by: Yijia Hua, et al.
Published: (2025-06-01)

Impact of Age and Menopausal Status on T-DM1 (Ado-Trastuzumab Emtansine) Treatment Outcomes in HER2-Positive Breast Cancer
by: Heves Surmeli, et al.
Published: (2025-06-01)

Evaluation of the Effect of Radiotherapy Timing on Toxicity in HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine During the Adjuvant Period
by: İlknur Deliktaş Onur, et al.
Published: (2025-04-01)

Analysis of trastuzumab therapy’s efficacy with or without pertuzumab combination in the metastatic HER2-positive breast cancer an oncology hospital of Pernambuco
by: Kaline Nascimento dos Santos Lima, et al.
Published: (2022-10-01)

Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis.
by: William Leung, et al.
Published: (2016-08-01)

Efficacy and safety of trastuzumab deruxtecan in Chinese patients with HER2-positive and HER2-low advanced breast cancer: a multicenter, observational, real-world study
by: Die Sang, et al.
Published: (2025-02-01)

The challenging management of acute mesenteric ischemia - too frail or too late?
by: Andreia Pinelo, et al.
Published: (2025-08-01)

“It is too soon… or too late:” Frantz Fanon’s Legacy in the French Caribbean
by: Andrew M. Daily
Published: (2015-11-01)

TULIP: The UK Life Induction Programme
by: Aman Sharma, et al.
Published: (2025-06-01)

Safety Assessment of Neoadjuvant Pertuzumab Combined with Trastuzumab in Nonmetastatic HER2-Positive Breast Cancer in Postmenopausal Elderly Women of South Asia
by: Nadia Hussain, et al.
Published: (2018-01-01)

Efficacy and safety of trastuzumab deruxtecan in HER2-positive breast cancer patients with brain metastases after failure of pyrotinib-based therapy
by: Jinmei Zhou, et al.
Published: (2025-05-01)

Neoadjuvant compared to adjuvant chemotherapy combined with trastuzumab in patients with HER2-positive breast cancer: a register-based cohort study
by: S. Hosseini-Mellner, et al.
Published: (2024-12-01)

Hedgehog inhibitors exert anti-proliferation effects and synergistically interact with trastuzumab in HER2-positive gastric cancer models
by: Zixin Yang, et al.
Published: (2025-05-01)

Too Little, Too Late: the Catalan Debacle in Light of the Slovenian Attainment of Independence
by: Carlos González-Villa, et al.
Published: (2023-12-01)

Social sciences research on infectious diseases of poverty: too little and too late?
by: José Azoh Barry
Published: (2014-06-01)